Alnylam's RNAi candidate wins orphan designation for hemophilia A

08/20/2013 | American City Business Journals

The FDA granted orphan-drug status to Alnylam Pharmaceuticals' ALN-AT3 as a treatment for hemophilia A, just a week after receiving the same designation for hemophilia B. ALN-AT3, an injectable RNAi therapeutic designed to treat several rare bleeding diseases, is expected to enter Phase I human studies next year.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI